
@getgroundedhlth co-founder - hr guru - @navalacademy grad - #disney fanatic - obsessed with #watches - fancy food & cocktail aficionado - photography #smiling
Asheville, NC
Joined August 2011
- Tweets1.4K
- Following105
- Followers390
- Likes804
Replying to @johnthebuyer @mcuban
@johnthebuyer yes TPAs resist but we have seen success when it's done agenticly and at scale.
1
21
After going to @shrm #Visionaries last month, I heard nothing less than 25% increase. A few were in the mid-30's.
Your 2027 renewal is being built on 9%. Highest medical cost trend in 17 years according to @PwC.
Ask which one your number is built on. We can show you were your money is going to help flatten the curve.
24
Eric Shangle retweeted
6 myths about your healthcare spend. A plan admin has fiduciary responsibility to know how advisors, carriers, TPAs, PBMs, and others are incentivized.
Replying to @DrugChannels
@DrugChannels it's about accountability. What is the incentive to switch and who owns making it happen. @getgroundedhlth launched to be the accountability layer. How can we help?
Payers save $3,820/month for cancer patients who used exclusively biosimilars instead of the reference product.
And only 1.2% switched to the reference product.
---
A recent cohort study published in JAMA Oncology tracked patients using bevacizumab, rituximab, or trastuzumab in commercial and Medicare claims from 2019 to 2024.
The study sorted them into four groups based on use in the first 12 months of treatment:
💊 59.4% used biosimilars exclusively
💊 32.5% used the reference product exclusively
💊 6.9% switched from the reference product to a biosimilar
💊 just 1.2% switched from a biosimilar to the reference product
Once patients start on a biosimilar, they mostly stay there.
The market share moving to biosimilar came primarily from new patients starting directly on a biosimilar, not from existing patients on the reference product converting.
---
Adjusted mean monthly payer costs across all four groups:
💰 Reference product only: $12,778.80/month
💰 Biosimilars only: $8,958.80/month (29.9% lower than reference-only)
💰 Reference product switched to biosimilars: $10,491/month (17.9% lower than reference-only)
💰 Biosimilars switched to reference product: $11,169/month (12.6% lower than reference-only)
Payers spent $3,820 less per month on patients who used biosimilars exclusively instead of the reference product.
Patients themselves saved $39.50/month out of pocket in the same comparison. Smaller patient savings than cited in other research, but these are also employer-sponsored plans that generally have richer benefits.
---
While payers do often save when switching to biosimilars, that's not always the case.
Plus, not all of the savings are passed onto the payer as we cover in this blog about hospital markups drugch.nl/4gHMIWI
It doesn't matter if the acquisition price of the product is 70% lower if the hospital marks up the price 400%, but this JAMA Oncology research indicates some of the savings are being shared with the payer and patient.
🔗 Source: JAMA Oncology jamanetwork.com/journals/jam…
61
Eric Shangle retweeted
Most scorecards grade you on things you already knew and can't act on.
Ours puts four things on a page & tells you what to do first: contract variance, emerging risk, price variance, and what each is worth if you act now.
#healthcarereform
I always asked where the increases were coming from and never got a direct answer. Identifying waste vs. value is a win for everyone.
Your 2027 renewal is being built on 9%. Highest medical cost trend in 17 years according to @PwC.
Ask which one your number is built on. We can show you were your money is going to help flatten the curve.
51
Up to 2/3 of the most expensive hospital stays growth wasn't explained by sicker patients...should have been ~13%. The gap is coding, and this data predates AI coding tools. @getgroundedhlth
1
34
Employers spend millions on health benefits with less visibility than they demand from a $500 software vendor. The wild part: the data to fix this is already public. Form 5500 filings and price transparency disclosures are sitting in the open, unread. Check out @getgroundedhlth
1
43
Replying to @mcuban
Thank you for lifting this up @mcuban - As an HR leader and co-founder of #GroundedHealth I know the pains of feeling like there is nothing we can do with rising costs. Let's flip the script and take control.
3
71
Eric Shangle retweeted
If you care about healthcare costs, read this.
getgroundedhealth.com/
How Letting Go Fuels Leadership Growth transformation-unfiltered.ca…
2
122
Go Navy...Beat Army. Another watch that means something to me. Read more about it and my journey here watchcrunch.com/swim97/posts…
1
3
175
It’s time I came out as a watch lover - I’ve been on #watchcrunch now for a bit and love the discussions - today I’ve got a Mission to Jupiter on NATO #moonswatch – at Asheville, NC
1
6
175
Excited to share that I’ll be speaking on a panel during @ConsensusDm’s Supercharge NC – Manufacturing and Energy Summit Thursday in Charlotte, NC.
Register to join elected officials, business leaders, industry experts & more: supercharge-nc.com/
1
122
Huge thanks to @BStulberg for leading an engaging discussion on rugged flexibility to thrive amidst change with the @PGRenewables team #allostasis #masterofchange
2
197
The "Power of Tomorrow" was alive last week at @PGRenewables Q1 #PineGateAcademy. Our team is powered by our values (grit, collaboration, creativity, & ownership) as they help lead the decarbonization of the US electricity sector.
157
















